Browse Articles

Discover research articles across all indexed journals

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study

Journal of Clinical Oncology Constance Thibault, Mostefa Bennamoun, Aude Fléchon et al. Jul 10, 2026 DOI: 10.1200/jco-25-03045

PURPOSE To evaluate the efficacy and safety of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) combined with durvalumab ± tremelimumab in patients with muscle-invasive bladder cancer (MIBC). METHODS NEMIO (ClinicalTrials.gov identifier: NCT03549715 ) is a multicenter, randomized, noncomparative phase II trial in cT2-T4a N0-1 cisplatin-eligible MIBC planned for radical cystectomy (RC). Patients received ddMVAC (cisplatin 70 mg/m 2 , methotrexate 30 mg/m 2 , doxorubicin 30 mg/m 2 , and vinblastine 3 mg/m 2 on days 1, and pegfilgrastim 6 mg on days 2) once every 2 weeks × four cycles plus durvalumab ± tremelimumab (durvalumab 1,500 mg and tremelimumab 75 mg) once every 4 weeks × two doses (C1D1 and C3D1) before RC. Coprimary end points (local assessment) were pathologic complete response (pCR; ypT0N0) and grade ≥3 treatment-related adverse events (TRAEs). The study was considered positive if the pCR rate was ≥45% and the rate of grade ≥3 TRAEs was ≤30%. RESULTS From 2018 to 2022, 119 patients received ddMVAC + durvalumab (n = 60) or ddMVAC + durvalumab + tremelimumab (n = 59); 113 underwent RC. The overall Bayesian posterior mean pCR rate was 48.70% (95% CI, 35.93 to 61.56) with doublet and 46.27% (95% CI, 33.92 to 58.85) with triplet. Among 103 patients with PD-L1 data (exploratory), Bayesian posterior mean pCR was 68.25% (95% CI, 54.57 to 80.49) in PD-L1–high tumors versus 33.49% (95% CI, 22.13 to 45.91) in PD-L1–low/negative tumors. Bayesian posterior mean grade ≥3 TRAEs occurred in 40.95% (95% CI, 32.50 to 49.69) overall (30.48% [95% CI, 20.00 to 42.08] doublet; 49.63% [95% CI, 37.55 to 61.73] triplet); immune-related adverse events occurred in 26.9% (grade ≥3 4.2%). Two-year event-free survival and overall survival rates were 75% and 85% in the doublet arm, and 77% and 88% in the triplet arm, respectively. CONCLUSION Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.

Hematological consequences of environmental change during dewilding of rhesus macaques

Nature Communications Annabelle Smith, Kasalina Kiwanuka, Gabriela Pessenda et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75260-w

Abstract The environment shapes immune system development and the regulation of inflammatory responses, however the hematological consequences of a major environmental change, such as those experienced during migration, remain poorly understood. Here, we assess the immunological consequences in male rhesus macaques as they transitioned from an outdoor provisioned environment to an indoor laboratory facility in a process we term ‘dewilding.’ Dewilding decreased neutrophils and increased lymphocytes, skewing toward a T H 1 response and increased T cell activation. In the gut microbiome, fungal abundance decreased while bacterial abundance increased. In the bone marrow, we observed a shift towards the less committed multipotent progenitor cells and increased erythrocyte progenitors, with upregulation of genes involved in hemoglobin control and erythropoiesis. Together, our findings illustrate how dewilding alters immune homeostasis, with implications for understanding immune adaptation in migrants from rural to urban environments and for optimizing immunization strategies during environmental change.

A dual-FBG Terfenol-D micro-displacement sensor for robust vehicular condition monitoring and intelligent transportation applications

Scientific Reports Shufang Wang, Yuanhao Xi, Siyuan Wang et al. Jul 10, 2026 DOI: 10.1038/s41598-026-58221-7

Key Methodological Considerations in the Interpretation of the CONKO-007 Trial

Journal of Clinical Oncology Orhun Akdogan, Ahmet Özet, Ozan Yazıcı et al. Jul 10, 2026 DOI: 10.1200/jco-25-02156

Cerebellum-inspired memtransistors enable emergent differentiation for hardware-efficient novelty detection

Nature Communications Min-A Kang, Spencer T. Brown, Nethmi Jayasinghe et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75212-4

Comparing vibrotactile stimulation to combined visual and auditory stimulation for 40 Hz gamma entrainment

Scientific Reports Yeongdae Kim, Ayush Choudhary, Hyeonseok Kim et al. Jul 10, 2026 DOI: 10.1038/s41598-026-60911-1

Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer

Journal of Clinical Oncology Dun-Chang Mo, Shang-Xiao Huang, Jian-Feng Huang et al. Jul 10, 2026 DOI: 10.1200/jco-25-02085

High-fidelity electrical detection of spin transport in graphene

Nature Communications Yijie Lin, Yuang Jie, Berke Köker et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75236-w

The effect of Punicalagin on tongue carcinoma cells viability and angiogenesis by regulating TGF-β signalling pathway: an in vitro study

Scientific Reports Suzan Seif Allah Ibrahim, Shahenda Mahmoud Farid, Iman Fathy et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61164-8

Abstract Punicalagin (PUN) is a major bioactive ellagitannin derived from pomegranate and showed a potential anticancer property on several cell lines, no studies investigate its effect on tongue carcinoma cells. The present study aimed to evaluate the cytotoxic and antiangiogenic effects of PUN on human tongue carcinoma cell line. The viability of the tongue carcinoma cell line was assessed following treatment with PUN (250, 200, 150, 100, and 50 µmol) for 24 h using MTT assay. In addition, the calculated (IC 50) was used for apoptosis validation using Annexin-V/Propidium Iodide (PI) flow cytometry, angiogenesis investigation using endothelial tube formation assay, and transforming growth factor-β (TGF-β) expression on human tongue carcinoma cells after treatment with Punicalagin using quantitative real-time polymerase chain reaction (qRT-PCR). The vitality of tongue carcinoma cells treated with PUN was 61.1 ± 4.36% and the untreated cells were 98 ± 2%. Flow cytometry confirmed that treatment with 185 µmol/mL of PUN induced significant apoptosis, yielding 51.3% apoptotic cells, 2.3% necrotic cells, and 46.7% viable cells. Regarding tubules no. HPF Untreated cells had a statistically significant higher value (5.83 ± 1.94) than cells treated with PUN (3.17 ± 1.17) ( p  = 0.023). The junction no/HPF had a higher value in untreated cells (5.50 ± 2.43) than in cells treated with PUN (3.33 ± 1.37) yet the difference was not statistically significant ( p  = 0.119). The Tube length showed a statistical significance between untreated cells (5.28 ± 0.77) and cells treated with PUN (1.83 ± 0.26) ( p  = 0.004). The values for lobules no/HPF were higher in untreated cells (2.67 ± 0.52) than in cells treated with PUN (1.67 ± 0.82) yet the difference was not statistically significant ( p  = 0.053). The expression of TGF-β gene showed a significantly higher value in untreated cells (0.97 ± 0.03) than in cells treated with PUN (0.02 ± 0.01) ( p  = 0.004). These initial in vitro observations indicate an anticancer effect of PUN on tongue carcinoma cells through the induction of apoptosis and inhibition of cell viability and angio-mimetic tube formation, closely correlating with the downregulation of TGF-β gene expression. This provides a possible preliminary therapeutic direction to the study of tongue carcinoma.

Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?

Journal of Clinical Oncology Timothy J. Brown, Muhammet Ozer, Udhayvir Singh Grewal et al. Jul 10, 2026 DOI: 10.1200/jco-26-00753

A symbiotic skin hydrogel interface enabled by flexible hydrogel network with embedded enhancement structure

Nature Communications Jun Ma, Mingxu Wang, Yongfeng Wang et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75372-3

Associations of plasma MMP-9 and MPO with functional outcome in moderate to severe acute ischemic stroke

Scientific Reports Vivian Vogt, Christoph Vollmuth, Guido Stoll et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61410-z

Abstract Inflammation plays a pivotal role in acute ischemic stroke (AIS), with neutrophil granulocytes acting as major contributors to the post-stroke immune response. Upon degranulation, neutrophils release matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO), both of which may influence functional outcomes following AIS. The aim of this study was to investigate the association between systemic levels of MMP-9 and MPO, functional outcome, and neutrophil counts in patients with moderate to severe AIS, with a focus on their pathophysiological relevance rather than standalone prognostic performance. This prospective single-center cohort study included patients with moderate to severe AIS in the anterior circulation (NIHSS score ≥ 6 points and /or indication for mechanical recanalization). Venous blood was sampled in order to assess plasma concentrations of MMP-9 via zymography as well as MPO plasma levels via ELISA. Furthermore, differential blood count was determined simultaneously to venous biomarker sampling. Poor outcome was defined as mRS score ≥ 3. Uni- and multivariable regression analyses were performed. Between 07/2020 and 09/2022 a total of 279 patients with blood samples taken up to 48 h after symptom onset with a median NIHSS score of 13 and a median age of 79 were included. Of these patients, 81.0% underwent mechanical recanalization and 42.7% received systemic thrombolytic therapy. Systemic MMP-9 and MPO plasma levels were significantly higher in patients with poor functional outcome compared to patients with good functional outcome at 3-months (MMP-9: 359.1 vs. 303.5 ng/ml, p  = 0.0006; MPO: 27.0 vs. 19.2 ng/ml, p  = 0.0010). Both biomarkers were associated with a poor outcome in unadjusted analyses [MMP-9: unadjusted OR = 15.63 (95% CI: 3.54-80.69), p  = 0.0005; MPO: unadjusted OR = 4.02 (95% CI: 1.84-9.21), p  = 0.0007]. In addition, MMP-9 and MPO concentrations correlated with neutrophil counts (MMP-9: r  = 0.39, p  < 0.0001; MPO: r  = 0.31, p  < 0.0001). In conclusion, systemic MMP-9 and MPO plasma concentrations are associated with functional outcome in patients with moderate to severe AIS and reflect neutrophil-driven inflammatory processes. Their value appears to lie in complementing established clinical predictors rather than serving as independent prognostic markers.

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19

Journal of Clinical Oncology Richard Cathomas, Ulf Petrausch, Stefanie Hayoz et al. Jul 10, 2026 DOI: 10.1200/jco-26-00845

PURPOSE Intravesical Bacillus Calmette-Guérin (BCG) is highly effective in non–muscle-invasive bladder cancer (MIBC) but has not been evaluated in MIBC. The recombinant BCG vaccine VPM1002BC (rBCG) has potentially enhanced immunogenicity and an improved safety profile. We investigated neoadjuvant intravesical rBCG combined with chemoimmunotherapy in MIBC. PATIENTS AND METHODS SAKK 06/19 was an open-label single-arm phase II trial for cT2-T4a N0-1 MIBC eligible for cisplatin and radical cystectomy with lymph node dissection (RC-LND). rBCG was instilled once per week three times starting on day 1. Atezolizumab was administered on day 1 for a total of four doses, and cisplatin/gemcitabine was started on day 22 for four cycles followed by RC-LND. Adjuvant atezolizumab was only administered in the case of >yT1 ypN0. The primary end point was centrally reviewed pathologic complete response (pCR, ypT0 ypN0). Based on Simon's minimax two-stage design with H0 pCR ≤35%, H1 pCR ≥55%, one-sided alpha 5%, and power 80%, 46 patients were needed. Secondary end points included pathologic overall response (PaR, ≤ypT1 ypN0), event-free survival (EFS), overall survival (OS), and safety. RESULTS Forty-seven patients were included between April 2022 and April 2025. Seven patients did not undergo RC-LND (six declined, one unfit for surgery). rBCG was instilled in 95%, and 78% had all three doses. Centrally reviewed pCR was 68% (27 of 40; one-sided 95% CI lower boundary 53%), and PaR was 83% (33 of 40; 95% CI, 67 to 93). Treatment-related adverse events (any grade, grade 3, grade 4) were 42%, 9%, and 0% for rBCG; 55%, 15%, and 2% for atezolizumab; and 96%, 38%, and 17% for chemotherapy. CONCLUSION To our knowledge, this is the first trial combining intravesical rBCG with chemoimmunotherapy in MIBC, demonstrating high pCR and PaR rates that warrant further investigation in prospective randomized trials.

Molecularly defined auditory neuron subtypes show different vulnerabilities to noise- and age-related synaptopathy in mice

Nature Communications Joy A. Franco, Taylor G. Copeland, Ryan D. Merrow et al. Jul 10, 2026 DOI: 10.1038/s41467-026-75275-3

Passive stretchable infrared modulator and reversible strain sensor based on a nano/microstructured metal–elastomer composite

Scientific Reports Rehab Ramadan, Vicente Torres-Costa, Raúl J. Martín-Palma Jul 10, 2026 DOI: 10.1038/s41598-026-60670-z

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors

Journal of Clinical Oncology Manish R. Sharma, John Powderly, Yasutoshi Kuboki et al. Jul 10, 2026 DOI: 10.1200/jco-26-01401

Observation of giant acoustoelectric currents in graphene on lead magnesium niobate–lead titanate

Nature Communications Hamed Atashbar, Hakhamanesh Mansoorzare, Tara Jabegu et al. Jul 10, 2026 DOI: 10.1038/s41467-026-74813-3

Abstract Acoustoelectric (AE) devices enable coupling between acoustic waves and mobile charge carriers, offering a route toward RF-to-DC conversion, RF power sensing, energy harvesting, and responsive sensing applications. The efficiency of this coupling depends on both the electromechanical properties of the piezoelectric substrate and the transport properties of the conductive film interacting with the surface acoustic wave (SAW). Here an AE SAW delay line platform is presented for generating large AE currents using graphene on lead magnesium niobate–lead titanate (PMN–PT). Leveraging graphene’s high carrier mobility and the strong electromechanical coupling of (111)-cut PMN–PT, this platform achieves giant AE current generation. Additionally, AE responsivity ( $${{\boldsymbol{{\mathscr{R}}}}}_{{{\bf{AE}}}}$$ R AE ) is introduced here as a figure of merit for comparing AE platforms. The platform comprises interdigitated transducers (IDTs) deposited and patterned on the bulk PMN–PT surface for launching SAW and a monolayer graphene film positioned within the SAW propagation region. Experimental measurements confirm generation of AE current and voltage within the SAW passband, with the AE current reaching up to 90.39 µA at an RF input power of 20 dBm, corresponding to an $${{\boldsymbol{{\mathscr{R}}}}}_{{{\bf{AE}}}}$$ R AE of 7.66 µA/(W·MHz). The reported AE current and AE responsivity outperform most of the previously reported platforms, validating the effectiveness of the proposed approach.

Abiotic Peptide-Like Bond Formation in Gas-Phase Nitrile–Water Clusters Driven by Vacuum Ultraviolet Photoionization

Journal of the American Chemical Society Yujian Li, Jiao Gao, Jiwen Guan et al. Jul 10, 2026 DOI: 10.1021/jacs.6c07744

Enhancing formation breakdown pressure using optimized drilling fluid additives with preventive wellbore strengthening approach

Scientific Reports Ahmadreza Abdshahi, Amir Farnia Shalmani, Seyed Morteza Mirabbasi et al. Jul 10, 2026 DOI: 10.1038/s41598-026-61491-w

Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer”

Journal of Clinical Oncology Rainer Fietkau, Sabine Semrau, Annett Kallies et al. Jul 10, 2026 DOI: 10.1200/jco-25-02926